Souhaitez-vous accéder aux communiqués récents ?

WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O’Brien, MD, MPH, for her research on the pneumococcal...

POCUS device and education bundle provides knowledge and experience to improve diagnostic accuracy, patient care, and clinical outcomes.

Boca Raton, Florida, May 13, 2025 (GLOBE NEWSWIRE) -- Nearly 3,000 healthcare professionals, a record-breaking turnout, converged on West Palm Beach this April for the American Academy of Anti-Aging...

Minneapolis, MN, May 13, 2025 (GLOBE NEWSWIRE) -- As working families search for meaningful summer opportunities for their young children, The Gardner School (TGS), an award-winning provider of...

HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable...

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD...

SAVANNAH, GA, May 12, 2025 (GLOBE NEWSWIRE) -- Telfair Museums announces a significant update to its Children’s Art Museum (CAM) with the opening of a new immersive exhibition on May 10, 2025 at the...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease  Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 ...